The story of the 1967 appearance of the powerful psychedelic 2,5‐dimethoxy‐4‐methylamphetamine (DOM, STP) commonly omits details and often includes hyperbole and inaccuracies. It is well known how and when the drug was first distributed to the public for free by Owsley Stanley, but the role that Alexander Shulgin played in providing that material is not as well understood. In the interest of transparency and historical accuracy, this article attempts to present an accurate account of this well‐known but inadequately detailed event. It follows DOM's development as an experimental substance believed to hold potential promise in psychotherapeutic applications through its appearance as a street drug generating bad press and a lasting bad impression among the public. One of the more interesting questions is why Shulgin would have taken such an immense risk in releasing this material to clandestine operators. While DOM was still legal it was also Dow's intellectual property, so discovery of his involvement could have jeopardized his career. The escape is especially curious as all fingers would logically first point towards Shulgin as the source. Drawing from published and unpublished sources, the authors attempt to suggest answers. DOM rapidly faded into oblivion before human pharmacodynamics and pharmacokinetics could be established. In this account, the reader is informed of the potential value that the compound played in non‐clinical molecular neuroscience, elucidating receptor specificity of new drugs, and how mistaken warnings about combining DOM with chlorpromazine led to better non‐pharmacological drug crisis response.

中文翻译：

---

2,5-二甲氧基-4-甲基苯丙胺（DOM、STP）的起源

1967 年强效致幻剂 2,5-二甲氧基-4-甲基安非他明 (DOM, STP) 出现的故事通常会忽略细节，并且常常包含夸张和不准确之处。众所周知，奥斯利·斯坦利首次向公众免费分发该药物的方式和时间，但亚历山大·舒尔金在提供该材料中所扮演的角色尚不清楚。为了透明度和历史准确性，本文试图准确描述这一众所周知但不够详细的事件。DOM 是一种实验性物质，被认为在心理治疗应用中具有潜在前景，因为它作为一种街头毒品出现，在公众中产生了负面报道和持久的不良印象。更有趣的问题之一是，为什么舒尔金会冒如此巨大的风险向秘密操作者泄露这些材料。虽然 DOM 仍然合法，但它也是陶氏的知识产权，因此如果发现他的参与可能会危及他的职业生涯。这次逃逸尤其令人好奇，因为所有的手指在逻辑上都会首先指向舒尔金作为来源。作者试图根据已发表和未发表的资料提出答案。在人类药效学和药代动力学建立之前，DOM 很快就被遗忘了。在这篇文章中，读者了解了该化合物在非临床分子神经科学中发挥的潜在价值，阐明了新药的受体特异性，以及关于 DOM 与氯丙嗪联合使用的错误警告如何导致更好的非药理学药物危机应对。